Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK and PD of JNJ-64140284 in Healthy Subjects
NCT03180762Phase 1Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2017
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JNJ-64140284 in epilepsy (8 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability at 40 days, Maximum Plasma Concentration (Cmax) of JNJ-64140284 and 6 more. Started May 2017; status: terminated.
02
Drugs
JNJ-64140284
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT03180762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03180762.